Cognitive behavioral therapy in prodromal psychosis

Current Pharmaceutical Design

Volumn 18, Issue 4, 2012, Pages 558-565

  Addington, Jean ^a   Marshall, Catherine ^a   French, Paul ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cognitive behavioral therapy; Prodromal psychosis

Indexed keywords

RISPERIDONE;

COGNITIVE THERAPY; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SUPPORTIVE THERAPY;

COGNITION DISORDERS; COGNITIVE THERAPY; EARLY DIAGNOSIS; HUMANS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84856546261     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799316082     Document Type: Review

References (71)

1. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003; 29(4): 703-15.
2. Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22(2): 283-303.
3. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: The Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39(11-12): 964-71.
4. McGorry PD, Yung A, Phillips L, et al. Randomized controlled trial of interventions designed to reduce risk of progression to firstepisode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59(10): 921-8.
5. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163(5): 790-9.
6. McGlashan TH, Zipursky R, Perkins DO, et al. The PRIME North America randomized double blind clinical trial of olanzapine vs placebo in patients at risk for being prodromally symptomatic for psychosis: I Study rationale and design. Schizophr Res 2003; 61(1): 7-18.
7. Miller TJ, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the prodromal sample. Schizophr Res 2003; 61(1): 19-30.
8. DeGrazia D. Ethical issues in early-intervention clinical trial involving minors at risk for schizophrenia. Schizophr Res 2001; 51(1): 77-86.
9. McGlashan TH. Psychosis treatment prior to psychosis onset: Ethical issues. Schizophrenia Res 2001; 51(1): 47-54.
10. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: Is it presently ethical? Schizophr Res 2001; 51: 31-8.
11. McGorry PD, Yung AR, Phillips L. Ethics in early intervention in psychosis: Keeping up the pace and staying in step. Schizophr Res 2001; 51(1): 17-29.
12. Bentall RP, Morrison AP. More harm than good: The case against using anti-psychotic drugs to prevent severe mental illness. J Ment Health 2002; 11(4): 351-6.
13. Addington J, Cornblatt B, Cadenhead K, et al. At clinical high risk for psychosis: Outcome for non-converters. Am J Psychiatry 2011; 168(8): 800-5.
14. Addington J. Assessment of early psychotic symptoms: Implications for intervention. European First Episode Schizophrenia Network Davos, Switzerland February 23rd 2002.
15. French P, Morrison AP. Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis. London: Wiley; 2004.
16. Lewis SW, Tarrier N, Haddock G, et al. Randomised controlled trial of cognitive-behavioural therapy in early schizophernia: acutephase outcomes. Br Psychiatry Suppl 2002; 53: 91-7.
17. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: I Meta-analyses of family intervention and cognitive behavior therapy. Psychol Med 2002; 32(5): 763-82.
18. Sensky T, Turkington D, Kingdon D, et al. A Randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000; 57(2): 165-72.
19. Tarrier N, Yusopoff L, Kinney C, et al. Randomized controlled trial of intensive cognitive behavior therapy for patients with chronic schizophrenia. Br Med J 1998; 317(7154): 303-7.
20. Birchwood M, Smith J, Macmillan F, et al. Predicting relapse in schizophrenia: The development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med 1989; 19(3): 649-56.
21. Gumley AI, O'Grady M, McNay L, et al. Early intervention for relapse in schizophrenia: results of a 12 month randomized controlled trial of cognitive-behavior therapy. Psychol Med 2003; 33(3): 419-31.
22. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: Findings from the North American Prodrome Longitudinal Study. Schizophr Bull 2009; 35(5): 894-908.
23. Yung AR, Phillips LJ, Yuen H, et al. Psychosis prediction: A 12- month follow-up of a high-risk ('prodromal) group. Schizophr Res 2003; 60(1): 21-32.
24. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. Am J of Epid 2002; 156(4): 319-27.
25. Morrison AP, French P, Wells A. Metacognitive beliefs across the continuum of psychosis: Comparisons between patients with psychotic disorders, patients at ultra-high risk and non-patients. Behav Res Ther 2007; 45(9): 2241-6.
26. McGorry P, Singh BS. Schizophrenia: Risk and Possibility of Prevention. In: Raphael B, Burrows GD, editors. Handbook of Studies on Preventive Psychiatry. Oxford: Elsevier Science; 1995. p. 491-514.
27. Roberts G. Delusional belief system and meaning in life: A preferred reality. Br J Psychiatry Suppl 1991; 158(14): 19-28.
28. Addington J, Addington D. Clinical trials during the prodromal stage of schizophrenia. Am J Psychiatry 2005; 162(7): 1387.
29. Morrison AP, Renton JC, Williams S, et al. Delivering cognitive therapy to people with psychosis in a community mental health setting: an effectiveness study. Acta Psychiatr Scand 2004; 110(1): 36-44.
30. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004; 185: 291-7.
31. Kay SR, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261-76.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: International Universities Press; 1994.
33. Hall RCW, Parks J. The modified global assessment of functioning scale: addendum. Psychosomatics 1995; 36(3): 267-75.
34. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9(1): 139-45.
35. French P, Shryane N, Bentall RP, Lewis SW, Morrison AP. Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. Br J Psychiatry Suppl 2007; 51: s82-s87.
36. Morrison AP, French P, Parker S, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007; 33(3):682-7.
37. Morrison AP. The interpretation of intrusions in psychosis: An integrative cognitive approach to hallucinations and delusions. Behav Cog Psych 2001; 29: 257-76.
38. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011; 125(1): 54-61.
39. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: The Calgary Depression Scale. Br J Psychiatry 1993; 163(22): 39-44.
40. Olivares J, Garcia-Lopez LJ, Hidalgo MD. The Social Phobia Scale and the Social Interaction Anxiety Scale: Factor structure and reliability in a Spanish speaking population. J Psychoed Assess 2001; 19: 69-80.
41. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale: The development and validation of a new scale adjustment for use in family intervention programmes with schizophrenic patients. Br J of Psychiatry 1990; 157: 853-9.
42. Bechdolf A, Veith V, Schwarzer D, et al. Cognitive-behavioral therapy in the pre-psychotic phase: An exploratory study. Psychiatry Res 2005; 136(2-3): 251-5.
43. Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog Med 1989; 80(12): 646-52.
44. Yung AR, Phillips LJ, McGorry P, et al. Prediction of psychosis: A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 1998; 172(33): 14-20.
45. Maurer K, Horrmann F, Schmidt M, Trendler G, Hafner H. The early recognition inventory: Structure, reliability and initial results. Schizophr Res 2004; 67(1): 34.
46. Montgomery S, Asbjornsen A. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-89.
47. Turner S, Beidel M, Dancu CV, Stanley M. An empirically derived inventory to measure social fears and anxiety. The Social Phobia and Anxiety Inventory (SPAI). Psych Assess: Am J Consult Clin Psychol 1989; 1: 35-40.
48. Kingdon DG, Turkington D. Cognitive-behavioral therapy of schizophrenia. London UK: The Guilford Press; 1994.
49. Fowler D, Garety P, Kuipers E. Cognitive behavior therapy for psychosis. Chichester UK: John Wiley & Sons Ltd; 1995.
50. Bechdolf A, Wagner M, Veith V, et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry 2007; 1: 71-8.
51. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 1984; 10(2): 300-12.
52. Bechdolf A, Schultze-Lutter F, Klosterkotter J. Self-experienced vulnerability, prodromal symptoms and coping strategies preceding schizophrenic and depressive relapses. Eur Psychiatry 2002; 17(7): 384-93.
53. Maurer K, Hormann F, Schmidt M, Trendler G, Hafner H. The early recognition inventory ERIraos: A two-step procedure for the detection of 'at risk mental states'. Schizophr Res 2004; 70(1): 76.
54. chooler N, Hogarty G, Weissman M. Social Adjustment Scale II (SAS II). In: Hargreaves W, Attkinson C, Sorenson J, editors. Materials for Community Mental Health Program Evaluators: Publications 79-328.Washington, DC: US Department of Health and Human Services; 1979. p. 290-302.
55. Morrison AP, Stewart SL, French P, et al. Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): trial rationale, design and baseline characteristics. Early Interv Psychiatry 2011; 5(1): 24-32.
56. Beck AT, Rush A, Shaw B. Cognitive Therapy of Depression. New York: Guilford Press; 1979.
57. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998; 36(4): 455-70.
58. Oliver JP, Huxley P, Priebe S, Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol 1997; 32: 76-83.
59. Phillips LJ, Nelson B, Yuen HP, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 2009; 43(9): 818-29.
60. Yung AR, Phillips LJ, Nelson B, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6- month analysis. J Clin Psychiatry 2011; 72(4): 430-40.
61. Yung A, Phillips L, McGorry PD. Establishing a clinical high risk service for ultra high risk individuals. In: Yung A, Phillips L, McGorry PD, editors. Treating Schizophrenia in the Prodromal Phase.New York: Taylor & Francis; 2004. p. 35-50.
62. Overall JE, Gorham DR. The brief psychiatric rating scale. Psych Rep 1962; 10: 799-812.
63. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
64. Garety PA, Fowler D, Kuipers E. Cognitive-behavioral therapy for medication-resistant symptoms. Schizophr Bull 2000; 26(1): 73-86.
65. Phillips LJ, McGorry PD, Yuen HP, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007; 96(1-3): 25-33.
66. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity, and sensitivity. Br J Psychiatry 1978; 133: 429-35.
67. Heinrichs DW, Hanlon T, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10(3): 388-98.
68. Walker EF, Cornblatt BA, Addington J, et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: A naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res 2009; 115(1): 50-7.
69. Garety PA, Fowler DG, Freeman D, Bebbington P, Dunn G, Kuipers E. Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: Randomised controlled trial. Br J Psychiatry 2008; 192(6): 412-23.
70. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) services: Dilution or reduction of risk? Schizophr Bull 2007; 33(3): 673-81.
71. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40(8): 616-22.